UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Mar

    28

    FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

    Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Mar

    15

    Voices on Value: Building a Sustainable Healthcare System Together – Our U.S. Sustainable Access and Pricing Transparency Report

    Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

    Mar

    07

    UCB Completes Acquisition of Zogenix, Inc.